Kurt Schrader sold Bio-Techne Corp (NASDAQ: TECH)
Kurt Schrader (D-OR), a U.S. Representative, has disclosed 1 trade in Bio-Techne Corp (TECH) since 2022, a single sale, worth an estimated $8K in disclosed volume (the midpoint of the dollar ranges members report, not exact amounts).
The trade highlighted here is a sale: Kurt Schrader sold $1,001 - $15,000 of Bio-Techne Corp (NASDAQ: TECH) on November 8, 2022. Since that trade, TECH is down -5.08% against the S&P 500 up +100.11%, an outperformance of -105.19%.
Data updated
Kurt Schrader's TECH trades vs the price
TECH is down -5.08% since Kurt Schrader sold on November 8, 2022, versus +100.11% for the S&P 500.
Performance since this trade
All Kurt Schrader TECH trades
Kurt Schrader & TECH trading FAQ
Is it legal for Kurt Schrader to trade Bio-Techne Corp (TECH) stock?
Yes. Members of Congress are allowed to trade individual stocks, including Bio-Techne Corp (TECH), but the STOCK Act of 2012 requires them to publicly disclose each transaction within 45 days. Quantellect tracks those disclosures; this page does not imply the trade was improper.
When did Kurt Schrader sell TECH?
Kurt Schrader disclosed a sale of $1,001 - $15,000 of Bio-Techne Corp (TECH) on November 8, 2022, according to public STOCK Act filings.
How has TECH performed since Kurt Schrader's trade?
Since Kurt Schrader sold TECH on November 8, 2022, the stock is down -5.08%, versus +100.11% for the S&P 500 over the same period, an outperformance of -105.19%.
How soon must members of Congress disclose a trade?
Under the STOCK Act, members of Congress must publicly report a covered transaction within 45 days of the trade. Filings can still be delayed, amended, or contain errors.
Where can I see all congressional TECH trades?
Quantellect tracks every disclosed congressional trade in Bio-Techne Corp (TECH) on the Bio-Techne Corp congressional trading page, which aggregates filings across all members of Congress.
Kurt Schrader's TECH tradesAll congressional filings for Bio-Techne CorpKurt Schrader's full profile
Not investment advice. Congressional trading data is sourced from public STOCK Act disclosures, which are filed with a delay and may contain errors or be revised. Estimated prices and post-trade returns are derived algorithmically from public filings and end-of-day market data and describe historical activity, not a recommendation. Always do your own research and consult a licensed financial advisor before making investment decisions.